NEW EPISODE: @tombollyky.bsky.social joins to explain the problems facing the US pharmaceutical market, Trump's new 100% tariffs and pricing deal with the United Kingdom, and the impact on American drug prices as well as supply chain security.
Thomas J. Bollyky (CFR) joins to explain the pricing and supply chain implications of Trump’s new tariffs on pharmaceutical products as well as the US-UK deal.
